Chitosan-functionalized bioplatforms and hydrogels in breast cancer: immunotherapy, phototherapy and clinical perspectives
Drug Discovery Today, vol.29, no.1, 2024 (SCI-Expanded, Scopus)
- Publication Type: Article / Review
- Volume: 29 Issue: 1
- Publication Date: 2024
- Doi Number: 10.1016/j.drudis.2023.103851
- Journal Name: Drug Discovery Today
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, Biotechnology Research Abstracts, Communication Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Metadex, Civil Engineering Abstracts
- Keywords: Chitosan, breast cancer, theranostic, drug and gene delivery, phototherapy
- Erciyes University Affiliated: Yes
Abstract
Breast cancer is the most common and malignant tumor among women. Chitosan (CS)-based nanoparticles have been introduced into breast cancer therapy as a way to increase the targeted delivery of drugs and genes to the tumor site. CS nanostructures suppress tumorigenesis by enhancing both the targeted delivery of cargo (drug and gene) and its accumulation in tumor cells. The tumor cells internalize CS-based nanoparticles through endocytosis. Moreover, chitosan nanocarriers can also induce phototherapy-mediated tumor ablation. Smart and multifunctional types of CS nanoparticles, including pH-, light- and redox-responsive nanoparticles, can be used to improve the potential for breast cancer removal. In addition, the acceleration of immunotherapy by CS nanoparticles has also been achieved, and there is potential to develop CS-nanoparticle hydrogels that can be used to suppress tumorigenesis.